Drug Search Results
Using advanced filters...
Advanced Search [+]

Onercept

Alternative Names: onercept
Clinical Status: Inactive
Latest Update: 2021-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TNF Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Psoriasis|Erythema|Arthritis, Psoriatic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Not Applicable

P3

Completed

Erythema|Psoriasis

2006-03-23

2022-03-12

Treatments

2004-000530-37

P3

Completed

Psoriasis|Erythema

2006-03-01

2022-03-12

Treatments

NCT00090129

P3

Terminated

Psoriasis|Arthritis, Psoriatic

2005-06-01

2019-03-21

Treatments